Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

The news sent U.S.-listed shares of Novo Nordisk 5% lower, while Eli Lilly stock ticked higher ... Stock Jumps on Early Stage Weight-Loss Drug Trial Results ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...